Amarillo Announces a Clinical Trial in Patients With Bone Marrow Disorders

Amarillo Biosciences will commence a study to test low-dose oral interferon alpha in 40 patients with rare bone marrow proliferative disorders.

The study will be conducted at a major cancer center in Texas with a leading medical authority that specializes in the treatment of these myeloproliferative disorders. Twenty patients, each with either polycythemia vera or primary thrombocythemia, will be given low-dose oral interferon alpha daily as a treatment to relieve the signs and symptoms associated with these disorders.